October 10, 2025

Seaport Criteria Bring Clarity to Myocarditis Grading

New guidelines combine H&E and CD3 staining to improve diagnostic accuracy and reproducibility worldwide

The Pathologist

October 10, 2025

Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress

“This study makes clear what many of us in oncology have suspected: Prior authorization isn’t just an administrative hurdle for clinicians; it’s a hidden second job for patients,” noted investigators....

The ASCO Post

October 09, 2025

Green Propellants and the Future of Metered Dose Inhalers

The pressure is on to reduce the carbon footprint of respiratory drugs by using next-generation green propellants

The Medicine Maker

October 08, 2025

Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO

Chronic myeloid leukemia (CML) is one of the success stories among the hematologic malignancies. Now, with decades of data informing its management, it is time to change some of the practices to which...

The ASCO Post

October 07, 2025

Nestor Beltre, M.D., Joins Baptist Health Miami Neuroscience Institute as a Neurologist

Board-certified neurologist Nestor Beltre, M.D., has joined Baptist Health Miami Neuroscience Institute.

Baptist Health South Florida

October 07, 2025

UCI Health launches first U.S. trial of nerve-blocking device for drug-resistant hypertension

A new clinical trial at UCI Health tests a novel device that could help millions with uncontrolled high blood pressure reduce or eliminate medications.

UCI Health

October 06, 2025

Can Nicotinamide Reduce the Risk of Skin Cancer Development?

A retrospective study aimed to determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.

The ASCO Post

October 03, 2025

FDA Sets Science Agenda for Generics: Priorities for 2026

The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI and modeling to modernize generics regulation.

The Medicine Maker

October 03, 2025

Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease

The FDA approved the estrogen receptor antagonist for adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic disease with progression aft...

The ASCO Post